Answers are grounded in this paper and cite their sources.
Respiratory syncytial virus (RSV) causes severe disease in young infants, particularly those with heart or lung diseases or born prematurely. Because no vaccine is currently available, monoclonal antibodies are used to prevent severe RSV disease in high-risk infants. While it is known that RSV evolves to avoid recognition by antibodies, screening tools that can predict which changes to the virus may lead to antibody resistance are greatly needed.
No takes yet. Share an insight, caveat, or question.
Beach et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: